Showing 4831-4840 of 5910 results for "".
- Lilly Teams Up With GSK, Vir to Test Antibody Combination Against COVID-19https://modernod.com/news/lilly-teams-up-with-gsk-vir-to-test-antibody-combination-against-covid-19/2478808/Eli Lilly is expanding the ongoing phase 2 BLAZE-4 trial to include testing a combination of its antibody treatment bamlanivimab with VIR-7831, a dual-action antibody being co-developed by GlaxoSmithKline and Vir Biotechnology, for use in low-risk patients with mild-to-moderate COVID-19, the comp
- Optomed Establishes a Scientific Advisory Boardhttps://modernod.com/news/optomed-establishes-a-scientific-advisory-board/2478806/Optomed announced it is establishing an international scientific advisory board consisting of globally recognized and scientifically merited medical doctors specializing in ophthalmology and neuro-ophthalmology, with advanced experience on artificial intelligence applied to detection of ophthalmi
- Verana Health Announces Real-World Data and Data Science Collaboration Agreement with Janssenhttps://modernod.com/news/verana-health-announces-real-world-data-and-data-science-collaboration-agreement-with-janssen/2478805/Verana Health announced a research collaboration agreement with Janssen Research & Development (Janssen). The research collaboration will focus on curating real-world data and driving data science applications in the areas of ophthalmology and urology. Financial terms of the agreement
- Neurophth Therapeutics Appoints Qiutang Li, PhD, as Chief Scientific Officerhttps://modernod.com/news/neurophth-therapeutics-appoints-qiutang-li-phd-as-chief-scientific-officer/2478800/Wuhan Neurophth Biotechnology, a developer of AAV-delivered gene therapies for the treatment of ocular diseases, announced the appointment of Qiutang Li, PhD, as Chief Scientific Officer. She will be mainly responsible for the company’s global R&D, IND portfolio strategy, and the establ
- Center For Sight is the First Practice Worldwide to Offer the OptiBlue IOLhttps://modernod.com/news/center-for-sight-is-the-first-practice-worldwide-to-offer-the-optiblue-iol/2478793/Center For Sight, which operates 14 eye clinics and surgery centers in Southwest Florida, is the first eye care practice to offer the new OptiBlue IOLs (Johnson & Johnson Vision), an advanced intraocular lens technology that filters violet light to improve contrast and clarity for cataract pa
- Merck Shuts Down Covid Vaccine Program After Lackluster Datahttps://modernod.com/news/merck-shuts-down-covid-vaccine-program-after-lackluster-data/2478791/Merck is discontinuing development of its two experimental Covid-19 vaccines after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines, according to a Bloomberg
- Genentech’s Faricimab Meets Primary Endpoint in Two Global Phase 3 Studies in Wet AMDhttps://modernod.com/news/genentechs-faricimab-meets-primary-endpoint-in-two-global-phase-3-studies-in-wet-amd/2478792/Genentech announced positive topline results from two identically designed global phase 3 studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, in people living with wet age-related macular degeneration (AMD). Both studies met their primary endpoint and showe
- Ace Vision Group Closes Series A Stock Round to Advance Ophthalmic Technologieshttps://modernod.com/news/ace-vision-group-closes-series-a-stock-round-to-advance-ophthalmic-technologies/2478790/Ace Vision Group announced that it closed a Series A preferred stock round totaling $13.3 million ($3.3 million oversubscribed) to continue development and commercialization of its VisioLite Ophthalmic Laser, a touchless therapeutic device being developed for the treatment of age-related vision d
- Lilly’s Bamlanivimab Cuts Risk of COVID-19 By Up to 80% at Nursing Homeshttps://modernod.com/news/lillys-bamlanivimab-cuts-risk-of-covid-19-by-up-to-80-at-nursing-homes/2478788/Eli Lilly announced Thursday that in a phase 3 study, bamlanivimab was shown to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. The findings from the BLAZE-2 COVID-19 prevention trial suggest the risk was decreased by up to
- VSY Biotechnology Introduces Protectalon DUO Kithttps://modernod.com/news/vsy-biotechnology-introduces-protectalon-duo-kit/2478778/VSY Biotechnology has introduced the Protectalon DUO Kit, which is designed to help eye care professionals meet their OVD needs at different stages of cataract surgery with a single kit. The Protectalon DUO Kit features a Dual Pack containing one unit cohesive (14 mg/mL, 1.1 mL) and one un